The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Oxidized Mitochondrial DNA May Contribute to Inflammation in SLE

Oxidized Mitochondrial DNA May Contribute to Inflammation in SLE

March 14, 2016 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Gio.tto_Shutterstock_DNASequence_500x270Reactive oxygen species (ROS) play an important role in cell signaling and homeostasis. They also seem to be critical for the formation of neutrophil extracellular traps (NETs), which typically form in response to pathogens. Unfortunately, although ROS are important for antimicrobial defense, they can be damaging, particularly to DNA. As a result—and not surprisingly, multiple mechanisms are in place to protect the body from the dangerous aspects of ROS, such as ROS-induced damage to genomic DNA. These protective mechanisms are particularly important because NETosis is a unique form of cell death in which genomic DNA and mitochondrial DNA are exposed to ROS. Mitochondrial DNA is especially vulnerable to ROS during NETosis, because it lacks protection from histones. Perhaps to compensate for this vulnerability, mitochondria that are damaged by ROS typically lose their membrane potential and undergo either mitophagy or extrusion. This process prevents the mitochondria from continuing to produce ROS and, therefore, limits damage to healthy tissue.

You Might Also Like
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
  • Aggregated Neutrophils Limit Inflammation
  • Is Chemical Exposure Linked to DNA Methylation Dysregulation in SLE Patients?
Also By This Author
  • Improved Pregnancy Outcomes for Women with SLE

However, researchers now have reason to believe these safety mechanisms may be disrupted in individuals with inflammatory disease. Evidence is accumulating to suggest that aberrant NETosis and/or impaired NET clearance may underlie the pathogenesis of such autoimmune disorders as systemic lupus erythematosus (SLE). In particular, studies have found that lupus lymphocytes have elevated mitochondrial ROS synthesis. The elevated ROS synthesis appears to be exacerbated by the fact that patients with lupus also have a unique subset of pro-inflammatory neutrophils known as low-density granulocytes (LDGs) that increase NET formation. The LDGs are distinct from the normal-density granulocytes (NDGs) seen in healthy individuals.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Christian Lood, PhD, visiting scientist at the University of Washington in Seattle, and colleagues explored the role of nicotinamide adenine dinucleotide phosphate oxidase and the mitochondrial electron chain in the generation of ROS. They published the results of their investigation of the role of mitochondria in inflammatory disease in the February issue of Nature Medicine.1 The investigators found oxidized mitochondrial DNA contributes to inflammation by upregulating type I interferon (IFN) signatures.

The researchers examined LDGs from individuals with SLE and compared them with NDGs from healthy controls. Not only did LDGs from patients with SLE have increased production of mitochondrial superoxide, but also the DNA that was spontaneously released by lupus LDG NETs was highly enriched for mitochondrial DNA. Finally, when the investigators looked for evidence of increased NETosis in patients with lupus, they found individuals with SLE had multiple biomarkers suggestive of NETosis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators then turned their attention to lupus-prone mice. When they treated these mice with a mitochondrial ROS scavenger, the mice displayed decreased autoimmunity, decreased type I IFN responses and an improved clinical phenotype. The results were consistent with the hypothesis that mitochondrial ROS promotes lupus-like disease. Thus, the researchers concluded that mitochondria play a role in autoimmune disease via contribution to the generation of NETs, as well as by contributing pro-inflammatory oxidized mitochondrial DNA.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016 Feb;22(2):146–153. doi: 10.1038/nm.4027. Epub 2016 Jan 18.

Editor’s note: The research team for this study is from the University of Washington in Seattle and the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). It was jointly led by Keith B. Elkon, University of Washington professor of Rheumatology, and Mariana J. Kaplan, chief of the NIAMS Systemic Autoimmunity Branch.

Pages: 1 2 | Multi-Page

Filed Under: Conditions, SLE (Lupus) Tagged With: DNA, Lupus, Mitochondrial DNA, NETosis, neutrophil extracellular traps, systemic lupus erythematosus (SLE)

You Might Also Like:
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
  • Aggregated Neutrophils Limit Inflammation
  • Is Chemical Exposure Linked to DNA Methylation Dysregulation in SLE Patients?
  • Researchers Target Altered T Cell Metabolism in SLE to Reverse Lupus Immuno-Phenotype

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)